Drugs / EFLEPEDOCOKIN ALFA

Trials 4 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/22 trials
Phase 1/2 NCT02406651 May 2016 → Apr 2019 acute graft versus host disease EVIVE Biotechnology Completed No outcome recorded
Phase 1/2 NCT02655510 Feb 2016 → Jun 2018 alcoholic hepatitis Mayo Clinic Completed No outcome recorded
Phase 22 trials
Phase 2 NCT05205668 Apr 2022 pneumonia EVIVE Biotechnology Withdrawn No outcome recorded
Phase 2 NCT04498377 Jan → Mar 2021 COVID-19 EVIVE Biotechnology Terminated No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07060638 Comparator Jan 2026 → Dec 2029 expected alcoholic hepatitis Samer Gawrieh Recruiting No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as EFLEPEDOCOKIN ALFA ChEMBL registry synonym — accepted as the source's own label CHEMBL4594542
Known as Eflepedocokina alfa ChEMBL registry synonym — accepted as the source's own label CHEMBL4594542
Known as Eflepedocokine alfa ChEMBL registry synonym — accepted as the source's own label CHEMBL4594542
Known as F-652 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05205668
3

NCT02406651

NCT02655510

NCT04498377

Known as IL-22 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07060638
Known as Il-22 dimer f-652 ChEMBL registry synonym — accepted as the source's own label CHEMBL4594542
Known as Promenakin ChEMBL registry synonym — accepted as the source's own label CHEMBL4594542
Modality Protein / enzyme biologic “a novel recombinant human interleukin-22 dimer, F-652” PMID 36399701 Mar 2023
Route Intravenous “F-652 will be administered intravenously at a rate of 100 mL/hour for one hour once per week for four weeks.” NCT02406651